Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
3.6
-191.53%
60%
—
-18.36%
40%
—
5 Years
Score3.6
Net Growth-191.53%
Net Trend60%
Net Income Consistency—
Rev Growth-18.36%
Rev Trend40%
Revenue Consistency—
Anika Therapeutics Inc fundamental performance
Between 2005 and 2025, revenue grew from $ 29M to $ 112M and net income went from $ 5M to -$ 10M. Revenue increased in 15 of those 20 years; net income in 13.
Across Anika Therapeutics Inc's full reported history, from 1993 to 2025, revenue grew from $ 2M to $ 112M and net income went from -$ 1M to -$ 10M. Revenue increased in 70% of the years measured; net income in 61%.
Anika Therapeutics Inc currently holds a 20-year HDB Score of 4.3 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 22.03 | — |
1 Year2025-08-12 | $ 8.72 | 152.64% |
5 Years2021-08-12 | $ 40.69 | -45.86% |
10 Years2016-08-12 | $ 48.79 | -54.85% |
20 Years2006-08-11 | $ 12.89 | 70.91% |
30 Years1996-08-09 | $ 4.50 | 389.56% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | 10 Years2016-08-12 | 20 Years2006-08-11 | 30 Years1996-08-09 |
|---|---|---|---|---|---|---|
| Price | $ 22.03 | $ 8.72 | $ 40.69 | $ 48.79 | $ 12.89 | $ 4.50 |
| Return | — | 152.64% | -45.86% | -54.85% | 70.91% | 389.56% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 120M | -$ 3M | $ 38M |
| 2025 | $ 112M | -$ 10M | $ 57M |
| 2024 | $ 119M | -$ 56M | $ 55M |
| 2023 | $ 120M | -$ 82M | $ 68M |
| 2022 | $ 156M | -$ 14M | $ 86M |
| 2021 | $ 147M | $ 4M | $ 94M |
| 2020 | $ 130M | -$ 23M | $ 98M |
| 2019 | $ 114M | $ 27M | $ 184M |
| 2018 | $ 105M | $ 18M | $ 159M |
| 2017 | $ 113M | $ 31M | $ 157M |
| 2016 | $ 103M | $ 32M | $ 124M |
| 2015 | $ 92M | $ 30M | $ 138M |
| 2014 | $ 105M | $ 38M | $ 106M |
| 2013 | $ 75M | $ 20M | $ 63M |
| 2012 | $ 71M | $ 11M | $ 44M |
| 2011 | $ 64M | $ 8M | $ 35M |
| 2010 | $ 55M | $ 4M | $ 28M |
| 2009 | $ 40M | $ 3M | $ 24M |
| 2008 | $ 35M | $ 3M | $ 43M |
| 2007 | $ 30M | $ 6M | $ 39M |
| 2006 | $ 26M | $ 4M | $ 47M |
| 2005 | $ 29M | $ 5M | $ 44M |
| 2004 | $ 26M | $ 11M | $ 39M |
| 2003 | $ 15M | $ 827K | $ 14M |
| 2002 | $ 13M | -$ 3M | $ 13M |
| 2001 | $ 11M | -$ 6M | $ 13M |
| 2000 | $ 16M | $ 173.55K | $ 18M |
| 1999 | $ 13M | -$ 2M | $ 14M |
| 1998 | $ 13M | $ 4M | $ 10M |
| 1997 | $ 12M | $ 3M | $ 22M |
| 1996 | $ 1M | -$ 2M | $ 2M |
| 1995 | $ 3M | -$ 2M | $ 2M |
| 1994 | $ 4M | -$ 1M | $ 2M |
| IPO1993 | $ 2M | -$ 1M | $ 5M |
Explore beyond ANIK
You're looking at Anika Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
